Biomedical Advanced Research and Development Authority (BARDA) has selected host-directed therapeutic candidates for inclusion in a phase 2 platform clinical trial to address acute respiratory distress syndrome (ARDS). Currently, no treatments are approved by the U.S. Food and Drug Administration (FDA) for ARDS.

ARDS is a life-threatening lung condition with multiple causes, including severe pneumonia and sepsis due to bacterial and viral infections such as influenza and SARS-CoV-2.

ARDS can lead to high rates of death among hospitalized patients or to long-term complications for patients who recover.

Since ARDS has multiple root causes, identifying new treatments for patients remains challenging.

Therefore, there is an urgent need to understand its clinical and biological features to better classify patients into sub-phenotypes that might be more responsive to a specific therapeutic.

Read More